120 related articles for article (PubMed ID: 38214034)
1. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
Hilley P; Wong D; Ma R; Peterson A; De Cruz P
Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
[TBL] [Abstract][Full Text] [Related]
2. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
Null K; Kumar V; Lissoos T; Luo M
J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
[TBL] [Abstract][Full Text] [Related]
3. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
Afzali A; Ogden K; Friedman ML; Chao J; Wang A
J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
[TBL] [Abstract][Full Text] [Related]
4. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
Harno-Tasihin J; Siregar L; Paajanen M; Arkkila P; Punkkinen J
Scand J Gastroenterol; 2024 Mar; 59(3):280-287. PubMed ID: 38006219
[TBL] [Abstract][Full Text] [Related]
5. Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].
Ventress E; Young D; Rahmany S; Harris C; Bettey M; Smith T; Moyses H; Lech M; Gwiggner M; Felwick R; Cummings JRF
J Crohns Colitis; 2022 Jul; 16(6):911-921. PubMed ID: 34935945
[TBL] [Abstract][Full Text] [Related]
6. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
7. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
8. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
[TBL] [Abstract][Full Text] [Related]
9. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
Qazi T; Shah B; El-Dib M; Farraye FA
Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
[TBL] [Abstract][Full Text] [Related]
11. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
[TBL] [Abstract][Full Text] [Related]
12. Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study.
Buisson A; Nachury M; Pereira B; Fumery M
Clin Gastroenterol Hepatol; 2024 May; 22(5):1127-1129.e2. PubMed ID: 37802269
[TBL] [Abstract][Full Text] [Related]
13. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease.
Haar GS; Vasudevan A; Curtain CM; van Langenberg DR
Res Social Adm Pharm; 2021 Aug; 17(8):1420-1425. PubMed ID: 33129684
[TBL] [Abstract][Full Text] [Related]
14. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
15. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
17. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
Fierens L; Liefferinckx C; Hoefkens E; Lobatòn T; Dreesen E; Sabino J; Ferrante M
J Crohns Colitis; 2022 Aug; 16(7):1059-1069. PubMed ID: 35078228
[TBL] [Abstract][Full Text] [Related]
18. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
Verma AM; Patel A; Subramanian S; Smith PJ
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
[No Abstract] [Full Text] [Related]
19. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
